|
|
||||||||
1 Division of Cardiology, This study evaluated the effects of
ceruloplasmin, the copper-containing blue oxidase of vertebrate plasma,
on the relaxation of rabbit aortic rings after endothelial release of
nitric oxide (NO). Ceruloplasmin at physiological, i.e., micromolar,
concentrations inhibited relaxation of rabbit aorta induced by
endothelium-dependent agonists like acetylcholine or ADP, whereas it
was ineffective toward vasodilation due to direct stimulation of smooth
muscle cells by nitroglycerin. The effect was reversible and specific for native, fully metalated ceruloplasmin, since relaxation was not
impaired by the heat-treated or metal-depleted derivatives. A trapping
mechanism, involving a direct interaction of NO or other NO-containing
species (like nitrosothiols and iron-dinitrosyls) with the copper sites
and/or with the free thiol of ceruloplasmin, could be safely
excluded on the basis of spectroscopic and chemical analyses of the
protein exposed to authentic NO, nitrosothiols, or iron-dinitrosyls.
The data presented in this paper constitute the first evidence of
impairment of the endothelium-dependent vasodilatation by a plasma
protein and may shed some light on the still uncertain physiological
role of ceruloplasmin.
nitric oxide; copper
NITRIC OXIDE (NO) is synthesized in many cellular
types, and it serves as an important intercellular mediator in the
vasculature, central nervous system, kidney, and endocrine system (21).
In the vascular compartment, NO produced by the endothelial NO synthase (NOS) diffuses into neighboring smooth muscle cells, where it induces
an increase of guanosine 3',5'-cyclic monophosphate levels leading to altered calcium mobilization and to vessel relaxation (28,
39). For this reason, NO has been identified as the endothelium-derived relaxing factor (EDRF) (8) and plays a key role in the complex regulation of local and systemic vascular resistance, distribution of
blood flow and oxygen delivery, and eventually regulation of arterial
pressure (40).
Little is known about the involvement of high-molecular-weight plasma
factors in the modulation of the endothelial NOS activity apart from a
well-established role for thrombin as a vasodilating agent. Recently,
it has been reported that immunoglobulins can inhibit the
thrombin-induced NO production by endothelial cells (35). On the other
hand, a specific role is emerging for some blood proteins in the
stabilization and targeting of NO to specific effectors. In this
respect, it has been suggested that albumin acts in the plasma as a
reversible trap for NO through
S-nitrosylation at its free cysteine
and that the resulting stable albumin-NO complex, in conjunction with
the extracellular pool of S-nitroso compounds (which also include
S-nitrosocysteine and
S-nitrosoglutathione), serves as a
source of NO, prolonging its half-life in the blood and buffering its
free concentration, and it eventually leads to vasorelaxation (14, 34,
36). Moreover, the existence of
S-nitrosylated hemoglobin possessing
vasorelaxing properties has been demonstrated in vivo and is related to
a dynamic cycle involving the uptake of NO in the lung and its release
during arterial-venous transit (13). Besides nitrosothiols, it has been
demonstrated that NO can be physiologically trapped within adducts with
thiols and iron. A role for these paramagnetic iron dinitrosyl
complexes (which have been shown to form in a number of different cell
types, including agonist-stimulated endothelial cells) has been
suggested in the control of blood vessel tone through transmembraneous
transport of NO (24).
Ceruloplasmin is the major extracellular copper-containing protein of
vertebrates, bearing six copper atoms bound at multiple sites and able
to interact with a number of ligands, including oxygen, azide, halides,
and NO. The protein circulates at micromolar concentrations in the plasma, and although its existence was recognized several years ago, its physiological role is still under debate. It is
certainly involved in iron metabolism, since it possesses a ferroxidase
activity (29), and individuals lacking a functional ceruloplasmin gene
have an impaired iron metabolism (11). The alternative function
proposed for ceruloplasmin, that it acts as a copper-transport protein
(3), cannot however be discounted yet. In fact, there is accumulating
evidence of a multifuctional role for this protein. To unravel new
roles of ceruloplasmin in the plasma, we investigated the effect of
ceruloplasmin on the endothelium-dependent relaxation of rabbit aorta.
Drugs and chemicals. The following
pharmacological agents were used: prostaglandin
F2 Preparation of ceruloplasmin.
Ceruloplasmin was purified from sheep, rabbit, or human plasma by
single passage of plasma on Sepharose 4B derivatized with
chloroethylamine, as previously described (2). Passage on quaternary
amino ethyl resin was used to concentrate the protein and to improve
the purity of the sample. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis analysis (17) revealed a high degree of purity (ranging
from 95 to 99% in different samples) and showed that over 90% of the protein was present as the unfragmented 130,000-Da component. The
physicochemical parameters (copper content, oxidase activity) and the
spectroscopic properties [optical, electron paramagnetic resonance (EPR)] of the purified proteins were in line with those already published (2, 25). In particular, different preparations had a
copper stoichiometry ranging from 5.1 to 5.5 Cu/molecule. The
stoichiometry of each preparation was not affected by treatment of the
protein with Chelex.
Copper-depleted ceruloplasmin (apoceruloplasmin) was prepared by
incubating the native protein with 50 molar excess
diethyldithiocarbamate (DDC) for 1 h at room temperature, centrifuging
at 25,000 g to remove the insoluble
copper-DDC complex, and then using exhaustive dialysis against 50 mM
phosphate buffer, pH 7, to eliminate unreacted DDC. Heat-inactivated
ceruloplasmin was obtained by heating the protein at 70°C for 90 min. Inactivation was assessed by irreversible loss of the optical
absorption at 610 nm. Both apo- and heat-treated ceruloplasmin had a
residual oxidase activity of ~10% with respect to the native
protein. The residual activity was consistent with the presence of
~10% unremoved copper in apoceruloplasmin and of ~10% of the
original absorption at 610 nm in the heat-treated protein.
Optical spectra were recorded on a Perkin-Elmer 330 spectrometer
equipped with a Haake Mod G temperature controller. X-band EPR spectra
were run at liquid nitrogen temperature on a Varian E-9 spectrometer
and at room temperature on a Bruker ESP 300.
Incubations of ceruloplasmin with NO were carried out as previously
described (27). To study the formation of nitrosothiols, we incubated
sheep ceruloplasmin or bovine serum albumin (BSA) under increasing
pressures of NO in the presence of ~0.05 atm of oxygen. Nitrites and
nitrosothiols were quantitated after Tracey (38) and Saville (33),
respectively. Free protein thiols were measured with
5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) after Ellman (5).
Dinitrosyl iron cysteine (DNIC 1:20) and DNIC-BSA were prepared
according to Boese et al. (1).
Experimental model. Experiments were
performed on thoracic aortas taken from male New Zealand White rabbits
(1.5-2 kg) anesthetized with ketamine. Immediately
after the rabbits were killed, the thoracic aortas were dissected free
and placed in cold modified Krebs-Ringer bicarbonate solution (mM
composition: 118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4,
25.0 NaHCO3, 0.026 calcium-EDTA,
and 11.1 glucose). They were cleared of connective tissue with care
taken not to damage the intimal surface, and 4- to 6-mm-long rings were
obtained.
Fine stainless steel wire clips were inserted through the lumen of the
rings, allowing them to be suspended for recording of isometric
tension. Rings were mounted in a jacketed organ bath filled with 25 ml
of Krebs-Ringer solution maintained at 37°C and equilibrated with
95% O2-5%
CO2, pH 7.4. Tension was measured by a force transducer, and changes in isometric force were recorded with a Gould 2400S direct-writing recorder coupled to bridge amplifier (Gould Instruments, Cleveland, OH). Rings were progressively stretched until the contractile response evoked by 100 mM KCl was maximal. The
vessels were left at this length throughout the study.
Experimental protocol. When the
optimal point of the length-tension curve of each vascular ring was
achieved, indomethacin (10 µM) was added to the organ chamber and
left throughout the experiment. To study endothelium-dependent and
independent relaxation, we contracted rings with 2 µM
PGF2 Data analysis and statistics. Data are
expressed as means ± SE. Relaxation to acetylcholine,
nitroglycerin, and ADP is expressed as the percent change relative to
the constriction produced by PGF2 Figure 1 shows the profile of the
endothelium-dependent relaxation of the aortic vessel to increasing
concentrations of acetylcholine in the presence of varying amounts
(1-10 µM) of sheep ceruloplasmin. The response of the vessel to
acetylcholine was found to be progressively impaired by increasing
concentrations of ceruloplasmin. Maximal relaxation was 87.7 ± 4.6% of baseline in control conditions and was already significantly
(P < 0.01) reduced at 3 µM
ceruloplasmin (60.5 ± 6.5%). Maximal relaxation observed
in the presence of 10 µM ceruloplasmin (42.3 ± 7.29%)
corresponded to over 50% inhibition. Computer extrapolation of the
effect of ceruloplasmin at infinite concentration of the protein
yielded a maximum inhibitory effect of ~75%. The effect was
specifically due to ceruloplasmin, since different preparations of the
protein with different degrees of purity (i.e., 95-99%) gave
essentially the same results, and was independent of the slight
variations in the copper stoichiometry between different batches of
ceruloplasmin. Treatment of ceruloplasmin with Chelex to remove loosely
bound metals did not affect the ability of the protein to impair
relaxation. Substitution of human or rabbit ceruloplasmin for the sheep
protein resulted in comparable effects on the acetylcholine-induced
relaxation of the vessel.
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
(PGF2
)-dinoprost
thromethamine (Upjohn, Kalamazoo, MI); nitroglycerin (Simes, Milan,
Italy); and acetylcholine chloride, indomethacin, and ADP (Sigma
Chemical, St. Louis, MO). Sepharose 4B and QAE-Sephadex A-50 were from
Pharmacia, Uppsala, Sweden. Chloroethylamine was from Carlo Erba,
Milan, Italy and was recrystallized before use as previously described (2). Metals were removed from the buffers with Chelex (Bio-Rad, Richmond, CA) before use. All other reagents were of
analytic grade and were used without further purification. Indomethacin was dissolved in 50% ethanol (final bath concentration of ethanol was
40 µM). All other drugs were dissolved in double-distilled water to
an appropriate concentration such that
0.1 ml of each solution was
added to the organ bath for each concentration.
. A cumulative
concentration-response curve to acetylcholine
(10
9-10
5
M) was obtained in all vessels studied to assure endothelium integrity.
After the first concentration-response curve, acetylcholine was washed
out, and rings were recontracted with 2 µM
PGF2
and divided into three
groups, each of six vessels, receiving different concentrations of
purified ceruloplasmin (1, 3, and 10 µM). After addition of
ceruloplasmin, a second dose-response curve to acetylcholine was
performed. In three experiments, relaxation to acetylcholine was also
repeated 30 min after washout of ceruloplasmin. In another group of six
vessels, the effects of the highest concentration of ceruloplasmin (10 µM) on the endothelium-dependent relaxation to ADP were tested.
Endothelium-independent vasodilation to nitroglycerin was studied in
six additional aortic rings before and after incubation with 10 µM
ceruloplasmin. In two additional groups of six vessels each,
endothelium-dependent relaxation to acetylcholine was evaluated before
and after incubation with 10 µM heat-treated or copper-free ceruloplasmin.
. The effects of
ceruloplasmin on the dose-response curve to the various agents were
tested for significance using analysis of variance with a design of
repeated measures.
![]()
RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

View larger version (24K):
[in a new window]
Fig. 1.
Cumulative relaxations to increasing concentrations of acetylcholine
for rabbit thoracic aorta preconstricted with prostaglandin
F2
(PGF2
) during control
conditions and after incubation with various concentrations of
ceruloplasmin (CP).
To test for the reversibility of the inhibitory effect of ceruloplasmin, rings treated with acetylcholine in the presence of 10 µM ceruloplasmin were extensively washed with buffer and allowed to reequilibrate for 30 min in the chamber bath. Maximal relaxation of these rings to acetylcholine was 81.6 ± 6.9 (P = not significant vs. control relaxation), indicating that the effect of ceruloplasmin was reversible.
The effect of ceruloplasmin was also tested on the
endothelium-dependent relaxation to a different agonist, namely ADP.
The corresponding curves are shown in Fig.
2. In this case, maximal relaxation was
83.4 ± 4.9% of PGF2
in
control conditions, and it was reduced to 49.2 ± 5.4% in the
presence of 10 µM ceruloplasmin (P < 0.01). In contrast, relaxation to nitroglycerin, an
endothelium-independent vasodilator, was not affected by 10 µM
ceruloplasmin (Fig. 3). These data suggest
that the effects of ceruloplasmin were specific for
endothelium-mediated vasodilation, whereas direct vascular smooth
muscle relaxation was not affected by the protein.
|
|
Two functionally inactive derivatives of ceruloplasmin, the heat-denatured and the copper-depleted proteins, were tested for their ability to inhibit the endothelium-dependent relaxation to acetylcholine. As shown in Fig. 4, neither derivative was effective, suggesting that the molecular architecture and the occupancy of the native sites by copper atoms in the protein must be preserved for the inhibition to occur. The slight inhibition observed with both heat-treated and apoceruloplasmin could be ascribed to the fraction of native holoprotein present in the samples (see MATERIALS AND METHODS).
|
It is known that ceruloplasmin can bind NO when exposed to high tensions of the authentic gas (10, 27). The binding occurs at the multiple copper sites of the protein and induces the variation of the optical absorbance at 610 nm for the blue copper sites, and in the 300- to 500-nm region for the other copper sites, the trinuclear cluster constituting the oxygen binding site. Figure 5 reports the change in the absorbance of sheep ceruloplasmin at some representative wavelengths in the 300- to 500-nm region as a function of NO pressure. We calculated the apparent affinity of ceruloplasmin for NO by fitting data at each wavelength to a single hyperbola. As shown Fig. 5, inset, the resulting values of P50 (NO pressure at which the optical properties of ceruloplasmin change to a 50% extent) depended on the wavelength of observation. This would suggest that NO interacts at multiple sites (or class of sites) on sheep ceruloplasmin with different affinities. More importantly, however, was the fact that P50 was never <0.15 atm NO, a pressure leading under our temperature and ionic strength conditions to ~0.2 mM dissolved NO.
|
Thiols can be reactive toward NO, forming nitrosothiols (RSNO) in the presence of oxygen (15). This has been shown to occur not only with low-molecular-weight thiols (cysteine, glutathione) but also with free cysteines in proteins like albumin (36) and hemoglobin (13), and a biological role for these latter adducts has been proposed. To test whether the single free cysteine of sheep ceruloplasmin could be S-nitrosylated, we first exposed ceruloplasmin to increasing pressures of NO in the presence of a small amount of oxygen. At variance with BSA, where ~0.7 RSNO per molecule formed on this treatment, no nitrosothiol formation could be detected with ceruloplasmin even at the highest NO pressure tested (1.5 atm). The formation of nitrosothiols on ceruloplasmin by transnitrosation reactions between the protein and low- or high-molecular-weight RSNO was also shown by the following experiment not to occur. Sheep ceruloplasmin was incubated with a large excess (10- to 100-fold) of either S-nitrosoglutathione (GS-NO) or S-nitroso-BSA (BSA-NO). At different times ranging from 5 min to 3 h, ceruloplasmin was quickly separated from the incubation mixture by the same method used for its purification, and the amount of RSNO was chemically assessed on both the protein and the bulk nitrosothiol. No RSNO could be detected on the protein at any time with any nitrosothiol, whereas determination of RSNO on bulk nitrosothiol gave indistinguishable values in samples incubated with and without ceruloplasmin. The low reactivity of the single free cysteine of ceruloplasmin is consistent with the observation that its rate of reaction with DTNB in the Ellman reaction was about 20-fold lower than that of BSA under comparable conditions (data not shown).
Previous evidence has been presented on the involvement of iron-dinitrosyls, complexes formed by NO, iron, and a thiol, in the NO-mediated vasorelaxation (23). To assess whether ceruloplasmin interacted with iron-dinitrosyl complexes, we first investigated whether paramagnetic DNIC 1:20 could form an adduct with sheep ceruloplasmin, analogously to what has been shown for albumin (1). EPR spectroscopy at room temperature was used in this respect to show that the line shape of DNIC 1:20 (which changes on binding of the complex to BSA) (Fig. 6, spectra A and B) was totally unaffected by ceruloplasmin (Fig. 6, spectrum C). The kinetics of NO release from the complex were then evaluated by measuring the formation of nitrites, and it was found that also in this respect the presence of ceruloplasmin was irrelevant. Finally, the EPR line shape of the high-molecular-weight complex BSA-DNIC was found to be insensitive to ceruloplasmin (Fig. 6, spectra B and D).
|
| |
DISCUSSION |
|---|
|
|
|---|
In the present study, we present evidence that ceruloplasmin, a circulating copper protein, efficiently impairs in vitro relaxation of the aorta to endothelium-dependent vasodilators. The effect was found to be reversible and specific for the endothelial functions, since the protein did not interfere with direct vascular smooth muscle relaxation stimulated by nitroglycerin. The presence of copper bound to ceruloplasmin was a requisite for the inhibitory effect of the protein, as demonstrated by the results with apoceruloplasmin. However, the inefficacy of the heat-denatured sample, where copper is still present, indicates that the mere presence of copper does not per se warrant the inhibitory properties of the protein and therefore that ceruloplasmin has to be in a native state to impair relaxation. Note that both removal of copper and protein denaturation affect the overall conformation of ceruloplasmin (26), which explains why both apo- and heat-treated ceruloplasmins were ineffective.
Different mechanisms can explain the observed phenomenon. The
hypothesis that ceruloplasmin simply acts as a trap for NO, thereby
preventing the messenger from activating guanylate cyclase within the
smooth muscle cell, is unlikely, because the affinity of ceruloplasmin
for NO, as monitored by the spectral changes of the protein, cannot
account for a significant trapping of NO under the conditions of the
relaxation experiments. As a matter of fact, because constitutive NOS,
including endothelial NOS, releases NO at micromolar concentrations at
the most, only a very small fraction of liberated NO would be trapped
by micromolar ceruloplasmin. Even when we consider that in our
experimental conditions there are many orders of magnitude more moles
of ceruloplasmin constantly flowing past the immediate vicinity of an
NO-producing cell, the kinetics of the interaction, which we had shown
to have a half-maximal time of ~15 min at submillimolar
concentrations of ceruloplasmin and of NO (18), are slow compared with
the more efficient (k = 2.3 × 106
M
2 · s
1)
reaction of NO with molecular oxygen (9). Also note that a high oxygen
tension was present in our buffers and that oxygen also continuously
flows at the cell surface under our conditions. The possibility that,
when exposed to the aorta, ceruloplasmin enters turnover conditions
(i.e., its copper atoms are partially reduced) and it traps NO in this
state, analogously to the known inhibition by NO turning over
cytochrome c oxidase (37), is also
unlikely, since we have previously shown that the affinity of the
copper sites of ceruloplasmin for NO is not appreciably dependent on
the metal reduction state (27).
Other lines of evidence help to rule out the "trapping" hypothesis. As shown in Fig. 1, the effect is dose dependent; however, ceruloplasmin never totally abolishes the effect of the vasodilator. In fact, its effect levels off at ~75% of inhibition at infinite concentration. This suggests that ceruloplasmin is not competing with other targets for NO. As a matter of fact, hemoglobin, which readily binds NO in the presence of oxygen, completely blunts the acetylcholine-induced relaxation (20). S-nitrosation of the free cysteine of ceruloplasmin, analogously to that reported for albumin (36), can be ruled out, since ceruloplasmin did not show to be prone to this modification either with authentic NO in the presence of oxygen or by transnitrosation with GS-NO or BSA-NO. This result is probably because of 1) the reduced accessibility of the thiol, as confirmed by the 20-fold difference in reactivity of DTNB toward ceruloplasmin vs. BSA; and 2) the fact that the high reactivity of the cysteine of albumin is mostly due to an abnormally low pK value (36), which is probably not the case for ceruloplasmin. Also note that formation of nitrosothiols like BSA-NO has a stabilizing effect on NO, improving rather than inhibiting its vasorelaxing properties.
It has been shown that iron-dinitrosyl complexes exist bound to the vascular endothelial wall and are capable of reaction with luminal components (24). Because it has been suggested that these complexes may represent the physiological form of EDRF (42), the possibility exists that ceruloplasmin prevents relaxation of the aorta by interacting with them. However, our EPR experiments did not reveal any significant interaction between ceruloplasmin and DNIC 1:20, and the rate of NO release by DNIC 1:20 was essentially unchanged by ceruloplasmin. Furthermore, a high-molecular-weight iron-dinitrosyl like BSA-DNIC was not destabilized by ceruloplasmin, suggesting that also in this respect ceruloplasmin is not simply a scavenger.
Ceruloplasmin could act through its ferroxidase activity by enhancing redox reactions between contaminant iron and NO. For instance, the iron-mediated conversion of NO to NO+ would be enhanced in the presence of a system capable of recycling Fe(II) to Fe(III). This hypothesis, however, has to be discarded, since under our experimental conditions (i.e., pH 7.4, high oxygen tension and micromolar concentrations of ceruloplasmin) the enzymatic conversion of Fe(II) to Fe(III) is expected to be only slightly more efficient than the spontaneous oxidation of divalent iron (7). If contaminant iron plays a role by itself, heat-treated ceruloplasmin should be as active as the native protein.
A second mechanism would involve a direct interaction of the protein with the vasodilator and/or with the agonist receptor on the endothelial membrane. Although this hypothesis cannot in principle be ruled out, it appears unlikely from the fact that ceruloplasmin equally inhibits the endothelium-dependent relaxation induced by two very different agonists, acetylcholine and ADP. A careful analysis of the data shown in Fig. 1 helps to rule out this second hypothesis. Should ceruloplasmin act through binding and sequestering acetylcholine, the rise in the relaxation value, which is observed at higher concentrations of the agonist and which is known to be due to the direct vasoconstrictor action of acetylcholine on smooth muscle cells (6), should not be observed at the same concentration of the agonist in the presence or absence of ceruloplasmin, at variance with the experimental data. Moreover, calculations performed on the same data presented in Fig. 1 reveal that, whatever the maximal relaxation value obtained in the various conditions, the concentration of acetylcholine needed to achieve half of that maximal relaxation is essentially the same (independent of the presence of ceruloplasmin), suggesting that the protein is not competitively impairing the interaction of the agonist with its receptor.
It is difficult at this stage to envisage the exact mechanism of the action of ceruloplasmin, since our data only safely exclude the trapping hypothesis. The alternative physiological roles of ceruloplasmin (i.e., as a ferroxidase and as a copper transport protein) both seem apparently unrelated to the impaired vasorelaxation observed in the presence of the protein, although others (4, 12, 30) studying the copper transport role of ceruloplasmin have demonstrated that the protein interacts with a number of cellular types and tissues, promoting copper entry possibly after binding to membrane receptors. It remains to be established whether these functionalities can be related to our observations.
Whatever the mechanism governing the inhibition of the endothelium-dependent action of vasodilators by ceruloplasmin, it remains that the phenomenon might have an extraordinary physiological relevance. Ceruloplasmin exerts its effect at micromolar concentrations, well within the range normally found in the plasma. Moreover, as an acute phase protein, the concentration of ceruloplasmin increases severalfold during a number of pathological conditions (16), easily reaching the levels at which the maximum effect on the aorta was observed. It might be speculated that these changes are accompanied by concomitant alterations in the effects of endogenous EDRF. In this respect, it is interesting to note that epidemiological observations have shown an association between increased serum ceruloplasmin (31) or serum copper (32) concentration (which is an indirect measure of ceruloplasmin levels) and the occurrence of acute vascular events such as myocardial infarction and stroke. Even more interesting is the fact that impaired endothelium functionality has been linked to a number of pathological processes, including atherogenesis (18, 41), and that ceruloplasmin levels in the blood are positively associated with the severity of coronary atherosclerosis (19, 22). It is unfortunate that, to date, no data are available on the vascular status of aceruloplasminemic individuals, who completely lack ceruloplasmin in their blood.
Taken together, the data of the present study suggest that ceruloplasmin could be involved in the physiological control of vascular tone and shed some light on a possible physiological role of this puzzling protein. Work is in progress to elucidate the mechanism of action of ceruloplasmin at the cellular level.
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported in part by Ministero dell' Università e della Ricerca Scientifica e Tecnologica 40% Funds and by Consiglio Nazionale delle Ricerche Grant 9502167.
| |
FOOTNOTES |
|---|
Address for reprint requests: G. Musci, c/o Dept. of Biochemical Sciences, Univ. La Sapienza, piazzale Aldo Moro, 5 00185 Rome, Italy.
Received 7 July 1997; accepted in final form 19 September 1997.
| |
REFERENCES |
|---|
|
|
|---|
1.
Boese, M.,
P. I. Mordvintcev,
A. F. Vanin,
R. Busse,
and
A. Mülsch.
S-nitrosation of serum albumin by dinitrosyl-iron complex.
J. Biol. Chem.
270:
29244-29249,
1995
2.
Calabrese, L.,
M. Carbonaro,
and
G. Musci.
Presence of coupled trinuclear copper cluster in mammalian ceruloplasmin is essential for efficient electron transfer to oxygen.
J. Biol. Chem.
264:
6183-6187,
1989
3.
Cousins, R. J.
Absorption, transport and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin.
Physiol. Rev.
65:
238-309,
1985
4.
Dameron, C. T.,
and
E. D. Harris.
Regulation of aortic Cu,Zn superoxide dismutase with copper. Caeruloplasmin and albumin re-activate and transfer copper to the enzyme in culture.
Biochem. J.
248:
669-675,
1987[Medline].
5.
Ellman, G. L.
Tissue sulfidryl groups.
Arch. Biochem. Biophys.
82:
70-77,
1959[Medline].
6.
Fish, R. D.,
E. G. Nabel,
A. P. Selwyn,
P. L. Ludmer,
G. H. Mudge,
J. M. Kirshenbaum,
F. J. Schoen,
R. W. Alexander,
and
P. Ganz.
Responses of coronary arteries of cardiac transplant patients to acetylcholine.
J. Clin. Invest.
81:
21-31,
1988.
7.
Frieden, E.,
and
H. S. Hsieh.
Ceruloplasmin: the copper transport protein with essential oxidase activity.
Adv. Enzymol.
45:
187-236,
1976.
8.
Furchgott, R. F.,
and
J. V. Zawadzki.
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.
Nature
288:
373-376,
1980[Medline].
9.
Goldstein, S.,
and
G. Czapski.
Kinetics of nitric oxide autoxidation in aqueous solution in the absence and presence of various reductants. The nature of the oxidizing intermediates.
J. Am. Chem. Soc.
117:
12078-12084,
1995.
10.
Gorren, A. C. F.,
E. de Boer,
and
R. Wever.
The reaction of nitric oxide with copper proteins and the photodissociation of copper-NO complexes.
Biochim. Biophys. Acta
916:
38-47,
1987[Medline].
11.
Harris, Z. L.,
Y. Takahashi,
H. Miyajima,
M. Serizawa,
R. T. A. MacGillivray,
and
J. D. Gitlin.
Aceruloplasminemia: molecular characterization of this disorder of iron metabolism.
Proc. Natl. Acad. Sci. USA
92:
2539-2543,
1995
12.
Horn Campbell, C.,
R. Brown,
and
M. C. Linder.
Circulating ceruloplasmin is an important source of copper for normal and malignant animal cells.
Biochim. Biophys. Acta
678:
27-38,
1981[Medline].
13.
Jia, L.,
C. Bonaventura,
J. Bonaventura,
and
J. S. Stamler.
S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control.
Nature
380:
221-226,
1996[Medline].
14.
Keaney, J. F., Jr.,
D. I. Simon,
J. S. Stamler,
O. Jaraki,
J. Scharfstein,
J. A. Vita,
and
J. Loscalzo.
NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties.
J. Clin. Invest.
91:
1582-1589,
1993.
15.
Kharitonov, V. G.,
A. R. Sundquist,
and
V. S. Sharma.
Kinetics of nitrosation of thiols by nitric oxide in the presence of oxygen.
J. Biol. Chem.
270:
28158-28164,
1995
16.
Kushner, I.
The acute phase response: an overview.
Methods Enzymol.
163:
373-383,
1982.
17.
Laemmli, U. K.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:
680-685,
1970[Medline].
18.
Lefer, A. M.,
and
X. L. Ma.
Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium.
Arterioscler. Thromb.
13:
771-776,
1993
19.
Männtäri, M.,
V. Manninen,
J. K. Huttunen,
T. Palosuo,
C. Ehnholm,
O. P. Heinonen,
and
M. H. Frick.
Serum ferritin and ceruloplasmin as coronary risk factors.
Eur. Heart J.
15:
1599-1603,
1994
20.
Martin, W.,
G. M. Villani,
D. Jothianandan,
and
R. F. Furchgott.
Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by haemoglobin and by methylene blue in rabbit aorta.
J. Pharmacol. Exp. Ther.
232:
708-716,
1985
21.
Moncada, S.,
R. M. J. Palmer,
and
E. A. Higgs.
Nitric oxide: physiology, pathophysiology and pharmacology.
Pharmacol. Rev.
43:
109-142,
1991[Medline].
22.
Mori, T.,
J. Sasaki,
H. Kawaguchi,
K. Handa,
Y. Takada,
A. Matsunaga,
S. Komo,
and
K. Arakawa.
Serum glycoproteins and severity of coronary atherosclerosis.
Am. Heart J.
129:
234-238,
1995[Medline].
23.
Mülsch, A.,
P. Mordvintcev,
A. F. Vanin,
and
R. Busse.
The potent vasodilating and guanylyl cyclase activating dinitrosyl iron (II) complex is stored in a protein-bound form in vascular tissue and is released by thiols.
FEBS Lett.
294:
252-256,
1991[Medline].
24.
Mülsch, A.,
P. I. Mordvintcev,
A. F. Vanin,
and
R. Busse.
Formation and release of dinitrosyl iron complexes by endothelial cells.
Biochem. Biophys. Res. Commun.
196:
1303-1308,
1993[Medline].
25.
Musci, G.,
M. C. Bonaccorsi di Patti,
and
L. Calabrese.
The state of the copper sites in human ceruloplasmin.
Arch. Biochem. Biophys.
306:
111-118,
1993[Medline].
26.
Musci, G.,
S. Di Marco,
G. C. Bellenchi,
and
L. Calabrese.
Reconstitution of ceruloplasmin by the Cu(I)-glutathione complex. Evidence for a role of Mg2+ and ATP.
J. Biol. Chem.
271:
1972-1978,
1996
27.
Musci, G.,
S. Di Marco,
M. C. Bonaccorsi di Patti,
and
L. Calabrese.
Interaction of nitric oxide with ceruloplasmin lacking an EPR-detectable type 2 copper.
Biochemistry
30:
986-9872,
1991[Medline].
28.
Nishimura, J.,
and
C. van Breemen.
Direct regulation of smooth muscle contractile elements by second messengers.
Biochem. Biophys. Res. Commun.
163:
929-935,
1988.
29.
Osaki, S.,
D. Johnson,
and
E. Frieden.
The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum.
J. Biol. Chem.
241:
2746-2757,
1966
30.
Percival, S. S.,
and
E. D. Harris.
Copper transport from ceruloplasmin: characterization of the cellular uptake mechanism.
Am. J. Physiol.
258 (Cell Physiol. 27):
C140-C148,
1990
31.
Reunanen, A.,
P. Knekt,
and
E. Aaran.
Serum ceruloplasmin level and the risk of myocardial infarction and stroke.
Am. J. Epidemiol.
136:
1082-1090,
1992
32.
Salonen, J. T.,
R. Salonen,
H. Korpela,
S. Suntioinen,
and
J. Tuomilehto.
Serum copper and risk of acute myocardial infarction: a prospective population study in men in eastern Finland.
Am. J. Epidemiol.
134:
268-276,
1991
33.
Saville, B.
A scheme for the colorimetric determination of microgram amounts of thiols.
Analyst
83:
670-672,
1985.
34.
Scharfstein, J. S.,
J. F. Keaney, Jr.,
A. Silvka,
G. N. Welch,
J. A. Vita,
J. S. Stamler,
and
J. Loscalzo.
In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols.
J. Clin. Invest.
94:
1432-1439,
1994.
35.
Schussler, O.,
F. Lantoine,
M.-A. Devynck,
D. Glotz,
and
M. David-Dufilho.
Human immunoglobulins inhibit thrombin-induced Ca2+ movements and nitric oxide production in endothelial cells.
J. Biol. Chem.
271:
26473-26476,
1996
36.
Stamler, J. S.,
O. Jaraki,
J. Osborne,
D. I. Simon,
J. F. Keaney,
J. Vita,
D. Singel,
R. Valeri,
and
J. Loscalzo.
Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin.
Proc. Natl. Acad. Sci. USA
89:
7674-7677,
1992
37.
Torres, J.,
V. Darlet-Usmar,
and
M. Wilson.
Inhibition of cytochrome c oxidase in turnover by nitric oxide: mechanism and implications for control of respiration.
Biochem. J.
312:
169-173,
1995.
38.
Tracey, W. R.
Spectrophotometric detection of nitrogen oxides using azo dyes.
Neuroprotocols
1:
125-131,
1992.
39.
Tworth, C. H.,
and
C. van Breemen.
Cyclic guanosine monophosphate-enhanced sequestration of Ca2+ by sarcoplasmic reticulum in vascular smooth muscle.
Circ. Res.
62:
961-964,
1988
40.
Umans, J. G.,
and
R. Levi.
Nitric oxide in the regulation of blood flow and arterial pressure.
Annu. Rev. Physiol.
57:
771-790,
1995[Medline].
41.
Vane, J. R.,
E. E. Anggard,
and
R. M. Botting.
Regulatory functions of the vascular endothelium.
N. Engl. J. Med.
323:
27-36,
1990[Medline].
42.
Vanin, A. F.
Endothelium-derivided relaxing factor is a nitrosyl iron complex with thiol ligands.
FEBS Lett.
289:
1-3,
1991[Medline].
This article has been cited by other articles:
![]() |
C. J. Sullivan, T. H. Teal, I. P. Luttrell, K. B. Tran, M. A. Peters, and H. Wessells Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats Physiol Genomics, October 17, 2005; 23(2): 192 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Jeremy, N. Shukla, G. D. Angelini, A. Day, I. Y.P. Wan, S. P. Talpahewa, and R. Ascione Sustained increases of plasma homocysteine, copper, and serum ceruloplasmin after coronary artery bypass grafting Ann. Thorac. Surg., November 1, 2002; 74(5): 1553 - 1557. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bianchini, G. Musci, and L. Calabrese Inhibition of Endothelial Nitric-oxide Synthase by Ceruloplasmin J. Biol. Chem., July 16, 1999; 274(29): 20265 - 20270. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |